The effects of p21 gene C98A polymorphism on development of uterine leiomyoma in southeast Iranian women

Salimi, Saeedeh; Hajizadeh, Azam; Yaghmaei, Minoo; S, Rezaie; Shahrakypour, Mahnaz; Teimoori, Batool; Parache, Mahboube; Naghavi, Anoosh; Mokhtari, Mojgan

doi:10.1007/s13277-016-5078-y

Cited by 8 publications

(10 citation statements)

References 30 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Growth factors may typically stimulate the angiogenesis of leiomyoma cells as compared with adjacent normal cells (Boehm et al, 1990;Di Lieto et al, 2005). Numerous investigations have revealed that both chromosome abnormalities in UL patients as well as genetic factors play key roles in UL pathogenesis in different countries, such as Iran (Gan et al, 2015;Salimi et al, 2015;Yaghmaei et al, 2015;Salimi et al, 2016). It is believed that ACE activity may be related to tumor growth and ACE inhibitors as well as angiotensin receptor blockers, thereby contributing to the suppression of tumor growth.…”

Section: Association Of Ace I/d and Agtr1 A1166c Gene Polymorphisms Amentioning

confidence: 99%

Association of ACE I/D and AGTR1 A1166C Gene Polymorphisms and Risk of Uterine Leiomyoma: A Case-Control Study

Keshavarzi¹,

Teimoori²,

Farzaneh³

et al. 2019

Asian Pac J Cancer Prev

Self Cite

View full text Add to dashboard Cite

Uterine leiomyomas (ULs) can be considered as the most common benign monoclonal tumors of the smooth muscle cells in the myometrium (Flynn et al., 2006). Evidence suggests that 70% of women may develop uterine fibroids. Although this disorder may be without signs and symptoms, in 40 to 50 percent of women over age 35 it may present as menorrhagia, infertility, pain, and recurrent pregnancy loss (RPL) (Marino et al., 2004; Wang et al., 2015). There are different risk factors influencing the growth of UL, including: ethnicity, smoking, family history, obesity, diet rich in meat, oral contraceptive pills, age, and biological biomarkers (Faerstein et al., 2001; Keshavarzi et al., 2017). Despite the various studies conducted to understand UL etiology, the exact mechanism of UL pathogenesis is not yet known clearly (Strawn et al., 1995). Several mechanisms have been suggested that have the effects on growth of UL, including ovarian angiogenesis, steroid hormones, growth factors, and

show abstract

Section: Association Of Ace I/d and Agtr1 A1166c Gene Polymorphisms Amentioning

confidence: 99%

Association of ACE I/D and AGTR1 A1166C Gene Polymorphisms and Risk of Uterine Leiomyoma: A Case-Control Study

Keshavarzi¹,

Teimoori²,

Farzaneh³

et al. 2019

Asian Pac J Cancer Prev

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, rs1059234 (C70T) is another P21 polymorphism, which is located downstream the stop codon in the 3′-untranslated region. This site is involved in cell proliferation, differentiation, and tumor suppression [14]. Several studies have indicated both genes and apoptotic pathways are important in the regulation on PE [15, 16].…”

Section: Introductionmentioning

confidence: 99%

Analysis of polymorphisms, promoter methylation, and mRNA expression profile of maternal and placental P53 and P21 genes in preeclamptic and normotensive pregnant women

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundPreeclampsia (PE), as a multisystem disorder, is associated with maternal hypertension and proteinuria. Apoptosis seems to be involved in the pathophysiology of PE, although its precise pathogenic mechanisms are not well established. In this study, we aimed to identify the association between maternal TP53-rs1042522, P21-rs1801270, and P21-rs1059234 polymorphisms and PE. In addition, we examined the effects of promoter methylation and TP53 and P21 polymorphisms on placental mRNA expression in PE women.MethodsThe blood of 226 PE women and 228 normotensive pregnant women was examined in this study. In addition, the placentas were genotyped in 109 PE and 112 control women. The methylation status was assessed by a methylation-specific PCR assay, while mRNA expression was examined via Quantitative Real Time PCR.ResultsThe maternal and placental P21-rs1801270 CA genotype had a significant association with the reduced risk of PE. In the dominant, recessive, and allelic models, maternal/placental P21-rs1059234 polymorphism had no statistically significant association with the risk of PE. On the other hand, the reduced risk of PE was associated with maternal, but not placental TP53-rs1042522 polymorphism in the dominant and recessive models. The maternal and placental P21-rs1801270 polymorphism was associated with PE risk. The maternal P21 Trs1059234Crs1801270 haplotype was associated with 3.4-fold increase in PE risk, However the maternal P21 Trs1059234Ars 1801270 haplotype and placental Crs1059234CA rs1801270 haplotype led to 0.5 and 0.4-fold decrease in PE risk, respectively. PE women showed 5.6 times higher levels of placental mRNA expression of TP53 gene, although it was not associated with rs1042522 polymorphism. The relative placental mRNA expression of P21 gene was 0.2 in PE women. It was also 2.4 times higher in individuals with rs1801270CA genotype than those with AA genotype. The hyper-methylation of P21 and TP53 genes in the promoter region was associated with a 3.4-fold and 3-fold increase in PE risk, respectively. However, no association was found between P21 and TP53 mRNA expression and promoter methylation.ConclusionIn conclusion, P21-rs1801270 and TP53-rs1042522 polymorphisms were involved in reduced risk of PE. P21-rs1801270 was associated with decreased P21 mRNA expression. The hyper-methylation of P21 and TP53 genes in the promoter region was associated with a higher PE risk.

show abstract

“…In the current study, we observed no significant association between rs1059234 and rs1801270 polymorphisms of P21 gene and PTC risk. However, the association between these polymorphisms, risk of squamous cell carcinoma, 36 sporadic colorectal cancer, 37 cervical cancer, 34 prostate cancer, 38 uterine leiomyoma, 24 and Gastrointestinal Tract Tumor 39 has been reported previously. We also found no significant association between P21 polymorphisms (rs1059234 and rs1801270) and pathological and clinical characteristics of PTC.…”

Section: Discussionmentioning

confidence: 92%

“…For genotyping of studied polymorphisms, the polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) was performed. The primer's sequence, PCR condition, and restriction enzyme used are presented in previous publications …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features

et al. 2020

Self Cite

View full text Add to dashboard Cite

Papillary thyroid cancer (PTC) is the most common thyroid malignancy. Genetic polymorphisms of the TP53 and P21 genes are the candidate variants in various cancers development. This study investigated whether the polymorphisms in TP53 (rs1042522) and P21 (rs1059234 and rs1801270) affect the risk of PTC and whether such the genotype of these polymorphisms is associated with pathological and clinical characteristics of PTC. A case–control study was conducted with 286 Iranian people, including 131 PTC cases and 155 healthy controls. The genetic polymorphisms were investigated by the polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP). Our results suggested that TP53‐rs1042522 CC genotype was significantly associated with protection against PTC, in the dominant, recessive and allelic models (OR = 0.4, 95%CI: 0.2–0.8, P = .008; OR = 0.5, 95%CI: 0.3–0.9, P = .01; OR = 0.6, 95%CI: 0.4–0.8, P = .002, respectively). The rs1042522 was associated with PTC patients with tumor size greater than 1 cm in dominant and recessive models (OR = 0.2, 95%CI = 0.04–0.9, P = .04 and OR = 0.3, 95%CI = 0.1–0.7, P = .009, respectively) and was associated with vascular invasion in dominant model (OR = 0.3, 95%CI = 0.1–0.7, P = .01). No correlation was identified between P21 rs1059234 and rs1801270 polymorphisms and risk of PTC and pathological and clinical characteristics of PTC. Genetic variations in rs1042522 might alter the PTC risk, which could affect tumor size and cause lower incidence of vascular invasion in PTC cases. This was the first report suggesting that no correlation was found between P21 rs1059234 and rs1801270 polymorphisms and PTC risk. Thus, more studies with a larger population size and different ethnic groups and functional assays are needed to confirm our results.

show abstract

The effects of p21 gene C98A polymorphism on development of uterine leiomyoma in southeast Iranian women

Cited by 8 publications

References 30 publications

Association of ACE I/D and AGTR1 A1166C Gene Polymorphisms and Risk of Uterine Leiomyoma: A Case-Control Study

Association of ACE I/D and AGTR1 A1166C Gene Polymorphisms and Risk of Uterine Leiomyoma: A Case-Control Study

Analysis of polymorphisms, promoter methylation, and mRNA expression profile of maternal and placental P53 and P21 genes in preeclamptic and normotensive pregnant women

The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features

Contact Info

Product

Resources

About